[Seronegative spondylarthritis].
Fasching
Peter
P
D018501:Antirheumatic Agents / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use; D003131:Combined Modality Therapy; D015796:HLA-B27 Antigen / Q000235:genetics; D006801:Humans; D007375:Interleukin-1 / Q000037:antagonists & inhibitors; D026741:Physical Therapy Modalities; D012217:Rheumatoid Factor / Q000097:blood; D025241:Spondylarthritis / Q000097:blood / Q000175:diagnosis* / Q000235:genetics / Q000534:rehabilitation; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D018501:Antirheumatic Agents; D001688:Biological Products; D015796:HLA-B27 Antigen; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D012217:Rheumatoid Factor